|  |  |  |  |
| --- | --- | --- | --- |
| **TOCCV1\_ver4.0 Interim Position Statement: Tocilizumab for patients admitted to ICU with COVID-19 pneumonia (adults)** | | | |
| **Patient NHS No:** |  | **Trust:** |  |
| **Patient Hospital No:** | \* | **Practice Code:** |  |
| **Patient's Initials and DoB:** |  | **GP Postcode:** |  |
| **Choose Consultant:** | |  |  | | --- | --- | |  | select |   help | | |
| **Consultant Name:** | \* | **Other Contact Details:** | \* |
| **Notification Email Address:**  (NHSE accredited domains ONLY) | | | |
| **Treatment Start Date:** | Clear selected value   \* | | |
|  | | | |

|  |  |
| --- | --- |
| **Please indicate whether patient meets the following criteria:** | **Please tick** |
| 1. I confirm that the patient is an adult with SARS-CoV-2 infection\*  \* In the absence of a confirmed virological diagnosis, tocilizumab should only be used when a multidisciplinary team have a high level of confidence that the clinical and radiological features suggest that COVID-19 is the most likely diagnosis. | |  | | --- | | Yes | | No |   \* Required |
| 2. I confirm intravenous tocilizumab has been prescribed as the patient is an adult who is critically ill\*\* with severe COVID-19 pneumonia requiring respiratory support (high-flow nasal oxygen, CPAP or non-invasive ventilation, or invasive mechanical ventilation)\*\*\* and **all**of the following apply:  • Less than 24 hours\*\*\*\* have elapsed since commencement of respiratory support (high-flow nasal oxygen, continuous positive airway pressure (CPAP) or non-invasive ventilation, or invasive mechanical ventilation)  • The patient will receive tocilizumab according to the Interim Clinical Commissioning Policy Position Statement: Tocilizumab for critically ill patients with COVID-19 pneumonia (adults)\*\*\*\*\* and does not meet any of the exclusion criteria  • The patient will receive one infusion of 8mg/kg (max 800mg)  \*\* In the context of the COVID-19 pandemic, treatment of patients critically unwell with COVID-19 can be in the following (critical care equivalent) settings: designated intensive care unit (ICU); surge ICU; or other hospital settings delivering an equivalent level of respiratory care (such as respiratory ward, infectious disease ward). \*\*\*The decision to treat with tocilizumab should be made by two consultants, of whom one should be experienced in respiratory support \*\*\*\* This can be extended up to a maximum of 48 hours for relevant clinical reasons, such as transfer of patients. However, the principle is to treat patients as early as possible in their critical illness \*\*\*\*\* As part of the interim position statement hospitals are strongly encouraged to submit data through the ISARIC 4C Clinical Characterisation Protocol (CCP) case report forms (CRFs), as coordinated by the COVID-19 Clinical Information Network (CO-CIN) | |  | | --- | | Yes | | No |   \* Required |